2.50
Hdl Handle:
http://hdl.handle.net/2336/15441
Title:
Infusion of plasma-derived mannan-binding lectin (MBL) into MBL-deficient humans.
Authors:
Valdimarsson, H
Citation:
Biochem Soc Trans. 2003, 31(Pt 4):768-9
Issue Date:
1-Aug-2003
Abstract:
Our first experience of mannan-binding lectin (MBL)-replacement therapy was with a patient experiencing recurrent erythema multiforme associated with reactivation of herpes simplex virus; his erythematous eruptions could be controlled with infusions of fresh frozen plasma containing MBL, but not with plasma lacking MBL. Some years later, we treated a young girl with recurrent, debilitating infections with purified MBL; this was also followed by a dramatic clinical improvement. We have now carried out a phase I clinical trial on 20 MBL-deficient, but healthy, adult volunteers. The MBL was prepared by the State Serum Institute in Copenhagen, Denmark, from blood donor plasma. Each volunteer received a total of 18 mg of MBL in three 6-mg doses given intravenously once a week over 3 weeks. The volunteers were monitored closely after each infusion and no adverse clinical or laboratory effects were observed. Laboratory parameters included C-reactive protein, various complement components, and antibodies to MBL, HIV and hepatitis viruses. C3a (the anaphylotoxin derived from complement component C3) was monitored for signs of complement activation, but no significant infusion-associated fluctuations were observed. Serum levels of MBL after each 6-mg infusion ranged between 1200 and 2500 ng/ml. The half-life of the infused MBL was about 70 h, or 3 days. It was concluded that infusion of purified MBL manufactured by the Danish State Serum Institute is a safe procedure. However, adults may have to be given 6 mg or more at least twice weekly to maintain protective plasma MBL levels in MBL-deficient individuals.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://www.biochemsoctrans.org/bst/031/0768/bst0310768.htm

Full metadata record

DC FieldValue Language
dc.contributor.authorValdimarsson, H-
dc.date.accessioned2007-12-20T10:51:39Z-
dc.date.available2007-12-20T10:51:39Z-
dc.date.issued2003-08-01-
dc.date.submitted2003-12-20-
dc.identifier.citationBiochem Soc Trans. 2003, 31(Pt 4):768-9en
dc.identifier.issn0300-5127-
dc.identifier.pmid12887300-
dc.identifier.doi10.1042/-
dc.identifier.urihttp://hdl.handle.net/2336/15441-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractOur first experience of mannan-binding lectin (MBL)-replacement therapy was with a patient experiencing recurrent erythema multiforme associated with reactivation of herpes simplex virus; his erythematous eruptions could be controlled with infusions of fresh frozen plasma containing MBL, but not with plasma lacking MBL. Some years later, we treated a young girl with recurrent, debilitating infections with purified MBL; this was also followed by a dramatic clinical improvement. We have now carried out a phase I clinical trial on 20 MBL-deficient, but healthy, adult volunteers. The MBL was prepared by the State Serum Institute in Copenhagen, Denmark, from blood donor plasma. Each volunteer received a total of 18 mg of MBL in three 6-mg doses given intravenously once a week over 3 weeks. The volunteers were monitored closely after each infusion and no adverse clinical or laboratory effects were observed. Laboratory parameters included C-reactive protein, various complement components, and antibodies to MBL, HIV and hepatitis viruses. C3a (the anaphylotoxin derived from complement component C3) was monitored for signs of complement activation, but no significant infusion-associated fluctuations were observed. Serum levels of MBL after each 6-mg infusion ranged between 1200 and 2500 ng/ml. The half-life of the infused MBL was about 70 h, or 3 days. It was concluded that infusion of purified MBL manufactured by the Danish State Serum Institute is a safe procedure. However, adults may have to be given 6 mg or more at least twice weekly to maintain protective plasma MBL levels in MBL-deficient individuals.en
dc.language.isoenen
dc.publisherPortland Press On The Behalf Of The Biochemical Societyen
dc.relation.urlhttp://www.biochemsoctrans.org/bst/031/0768/bst0310768.htmen
dc.subject.meshClinical Trials, Phase I as Topicen
dc.subject.meshHumansen
dc.subject.meshImmune System Diseasesen
dc.subject.meshMannose-Binding Lectinen
dc.subject.meshDrug Therapyen
dc.titleInfusion of plasma-derived mannan-binding lectin (MBL) into MBL-deficient humans.en
dc.typeArticleen
dc.identifier.eissn1470-8752-
dc.contributor.departmentDepartment of Immunology, Institute of Medical Laboratory Sciences, Landspítali, 101 Reykjavik, Iceland. helgiv@landspitali.isen
dc.identifier.journalBiochemical Society transactionsen

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.